PMID- 23412108
OWN - NLM
STAT- MEDLINE
DCOM- 20130423
LR  - 20211021
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Print)
IS  - 0007-0920 (Linking)
VI  - 108
IP  - 4
DP  - 2013 Mar 5
TI  - Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the 
      mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma.
PG  - 826-30
LID - 10.1038/bjc.2013.46 [doi]
AB  - BACKGROUND: Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine 
      malignancy without an available effective systemic chemotherapy. Insulin growth 
      factor 2 (IGF-2) overexpression leading to the activation of the IGF-1 receptor 
      (IGF-1R)/mammalian target of rapamycin (mTOR) pathway is well described in ACC. 
      Cixutumumab, a fully human IgG1 monoclonal antibody directed at IGF-1R was 
      combined with temsirolimus on the basis of preclinical data. METHODS: Patients 
      received cixutumumab, 3-6 mg kg(-1) intravenously (IV) weekly, and temsirolimus, 
      25-37.5 mg IV weekly (4-week cycles), with restaging after 8 weeks. RESULTS: 
      Twenty-six patients were enrolled (13 (50%) men); median age, 47 years; median 
      number of prior therapies, 4. Five patients previously received an IGF-1R 
      inhibitor and one, temsirolimus. The most frequent toxicities, at least possibly 
      drug related, were grade 1-2 thrombocytopenia (38%), mucositis (58%), 
      hypercholesterolaemia (31%), hypertriglyceridemia (35%), and hyperglycaemia 
      (31%). In all, 11 of 26 patients (42%) achieved stable disease (SD) >6 months 
      (duration range=6-21 months) with 3 of the 11 having received a prior IGF-1R 
      inhibitor. CONCLUSION: Cixutumumab combined with temsirolimus was well tolerated 
      and >40% of patients achieved prolonged SD.
FAU - Naing, A
AU  - Naing A
AD  - Department of Investigational Cancer Therapeutics (Phase I Clinical Trials 
      Program), The University of Texas MD Anderson Cancer Center, 1515 Holcombe 
      Boulevard, Houston, TX 77030, USA. anaing@mdanderson.org
FAU - Lorusso, P
AU  - Lorusso P
FAU - Fu, S
AU  - Fu S
FAU - Hong, D
AU  - Hong D
FAU - Chen, H X
AU  - Chen HX
FAU - Doyle, L A
AU  - Doyle LA
FAU - Phan, A T
AU  - Phan AT
FAU - Habra, M A
AU  - Habra MA
FAU - Kurzrock, R
AU  - Kurzrock R
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - U01CA62487/CA/NCI NIH HHS/United States
GR  - U01 CA062487/CA/NCI NIH HHS/United States
GR  - U01CA62461/CA/NCI NIH HHS/United States
GR  - U01 CA062461/CA/NCI NIH HHS/United States
GR  - UL1 RR024148/RR/NCRR NIH HHS/United States
GR  - R21CA13763301A1/CA/NCI NIH HHS/United States
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20130214
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2285XW22DR (cixutumumab)
RN  - 624KN6GM2T (temsirolimus)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Adrenocortical Carcinoma/drug therapy
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal/*administration & dosage
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Sirolimus/administration & dosage/*analogs & derivatives
MH  - Young Adult
PMC - PMC3590681
EDAT- 2013/02/16 06:00
MHDA- 2013/04/24 06:00
PMCR- 2014/03/05
CRDT- 2013/02/16 06:00
PHST- 2013/02/16 06:00 [entrez]
PHST- 2013/02/16 06:00 [pubmed]
PHST- 2013/04/24 06:00 [medline]
PHST- 2014/03/05 00:00 [pmc-release]
AID - bjc201346 [pii]
AID - 10.1038/bjc.2013.46 [doi]
PST - ppublish
SO  - Br J Cancer. 2013 Mar 5;108(4):826-30. doi: 10.1038/bjc.2013.46. Epub 2013 Feb 
      14.